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Introduction
Clinical magnetic resonance imaging (MRI) is at the forefront
of disease diagnosis. It uses strong magnetic fields, radio
waves, and field gradients to give detailed images of human
anatomy. However, due to the inherent low sensitivity of MRI,
almost all clinical applications detect water due to its high con-
centration in the body. Hyperpolarization methods turn typical-
ly weak MRI responses into strong signals and thus open the
door to new diagnostic techniques. For example, dynamic nu-
clear polarization (DNP) has been used to create the signal
strength necessary to track the in vivo metabolism of pyruvate
in prostate tumors,[1] whilst spin exchange optical pumping
(SEOP) of noble gases has allowed the diagnosis of pulmonary
diseases.[2]
An alternative low-cost approach to hyperpolarization uses
parahydrogen (p-H2) to create a non-Boltzmann nuclear spin
distribution without changing the identity of the molecule of
interest. This technique is known as signal amplification by re-
versible exchange (SABRE) and is shown schematically in
Figure 1.[3] It can enhance the signals detected by MRI and nu-
clear magnetic resonance (NMR) spectroscopy across a wide
range of nuclei such as 1H, 13C, 15N and others.[4] It works by
harnessing the latent polarization of p-H2 through binding to a
metal catalyst, typically [Ir(H)2(Sub)3(IMes)]Cl,
[5] as hydride li-
gands. Simultaneous binding of the substrate allows spontane-
ous transfer of polarization through the scalar coupling net-
work at low magnetic fields.[6] Subsequent substrate dissocia-
tion from the catalytic complex allows buildup of hyperpolar-
ized substrate in solution.
A recent study showed that 2H labeling a series of nicotina-
mide and methyl nicotinate molecules can simultaneously im-
prove their SABRE-enhanced NMR and MRI detection and de-
crease magnetic relaxation. The optimal substrate in this study
was methyl-4,6-d2-nicotinate (d2-MN), which gave up to 50%
polarization in conjunction with T1 relaxation values approach-
ing 2 minutes.[7] This makes d2-MN an ideal candidate for
in vivo detection. However, despite some applications of
methyl nicotinate (MN) in cosmetic and veterinary pharmaceu-
tics, the effect of selective deuteration has not been studied.
The isotopic labeling of drug molecules is a well-established
route to modify their safety and/or efficacy.[8] Deuteration pri-
marily affects the biological fate of drugs that are metabolized
through a pathway that involves hydrogen–carbon bond
breaking, as significant rate changes can occur due to the ki-
netic isotope effect. The metabolic pathway of nicotinic acid
derivatives typically proceeds via formation of the N-oxide,
though routes involving 6-hydroxy species are also known. For
this reason the toxicity of d2-MN in comparison with MN is de-
termined here using in vitro cytotoxicity analysis.
Figure 1. Schematic representation of the SABRE effect.
Production of a biocompatible hyperpolarized bolus for signal
amplification by reversible exchange (SABRE) could open the
door to simple clinical diagnosis via magnetic resonance imag-
ing. Essential to successful progression to preclinical/clinical
applications is the determination of the toxicology profile of
the SABRE reaction mixture. Herein, we exemplify the cytotox-
icity of the SABRE approach using in vitro cell assays. We con-
clude that the main cause of the observed toxicity is due to
the SABRE catalyst. We therefore illustrate two catalyst removal
methods: one involving deactivation and ion-exchange chro-
matography, and the second using biphasic catalysis. These
routes produce a bolus suitable for future in vivo study.
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Another potential source of toxicity that arises from the
SABRE technique is the iridium catalyst itself. Whilst some data
on the adverse effects of iridium salts has been reported[9] ,
little information is known about organo-iridium complexes.[10]
Therefore, we present a thorough investigation into the poten-
tial toxicity of the metal catalyst in conjunction with solvent
and substrate effects. We determine the biocompatibility of
the SABRE reaction by performing in vitro cytotoxicity analysis
on human cell lines and present a method for depletion of the
catalyst from solution in order to create a biocompatible bolus
that could be progressed to in vivo measurement.
Results and Discussion
Evaluating the cytotoxicity of SABRE substrate
Methyl-4,6-d2-nicotinate (d2-MN) has been reported to give the
highest 1H polarization levels by SABRE to date.[7] From a bio-
logical perspective, MN is widely used as rubefacient in cos-
metics due to its percutaneous penetration properties upon
topical application and moreover known for its vasodilatory ef-
fects at lower doses and inflammatory response at higher
doses.[11] Given the substantial SABRE enhancement levels and
biological applicability, d2-MN is considered an ideal candidate
for probing on in vitro/in vivo tests for SABRE detection. How-
ever, whether d2-MN retains the characteristics of MN is still
unclear. In this study, we use d2-MN as a model substrate to as-
certain the broader SABRE toxicology profile.
To establish the effect of selective deuteration on toxicity we
began by determining the IC50 (half maximal inhibitory concen-
tration) values of MN and d2-MN. For this, well-established
cancer cell lines of human origin were treated with either MN
or d2-MN at varying concentrations for up to 48 h, and the via-
bility was assessed by the MTT method.[12] The results obtained
for each cell line are shown in Table 1. The IC50 value for MN
was found to range between 12.6–33.3 mm across the cell
lines, and interestingly, despite the deuterium labeling, a com-
parison of the IC50 values indicates that the toxicity levels of
d2-MN are similar to those of MN. Importantly, both substrates
have millimolar IC50 values (Table 1) and are within the concen-
tration range used in a typical SABRE reaction (mm). It is noted
here that these results are based on the solubility of the sub-
strates directly in the high volume of the cell culture medium,
and it is still unclear how the effect would be under the condi-
tions of SABRE, in which different solvents are used. Neverthe-
less, these data provide a reference IC50 value for optimizing
SABRE for further analysis. From this analysis, we conclude that
deuteration of the methyl nicotinate has no quantifiable effect
in modulating toxicity across the cell lines studied here.
Effect of SABRE solvents on cell viability
SABRE-induced polarization levels are typically highest in alco-
hol solvents such as [D4]methanol or [D6]ethanol.
[7, 13] However,
some applications can produce hyperpolarized substrates in
aqueous solution, though enhancement levels are typically re-
duced.[14] To create a biocompatible hyperpolarized bolus with
high polarization levels, it has been suggested that the hyper-
polarization step should be carried out in [D6]ethanol prior to
dilution with D2O.
To assess the toxicity of these solvent mixtures, we per-
formed an appropriate cell viability assay on A549 and MCF7
cells, which were treated with various dilutions of [D6]ethanol
in D2O. As shown in Figure 2, the viability of both cell lines
was significantly decreased if [D6]ethanol (100%) was added to
cell culture medium and treated for a short time (6 h). Con-
versely, over the same time period (6 h), 50% [D6]ethanol in
D2O (1:1) showed no change in cell viability. Extending the
treatment durations to 24 h, however, significantly decreased
the viability (Figure 2B). We found that treatment of cells in a
30% [D6]ethanol in D2O (30:70) solution did not show toxicity
to cells over long treatment times relative to other deuterated
solvent mixtures (Figure 2B and Supporting Information Fig-
ure S1). Together the results indicate that a significant decrease
in cell viability is evident when the solvent contained
[D6]ethanol concentrations higher than or equal to 50%. The
behavior of analogous protio solvent mixtures is similar (Sup-
porting Information Figure S2). From these in vitro cytotoxicity
analyses on SABRE solvents, we conclude that to achieve opti-
Table 1. Comparing the IC50 values of methyl nicotinate (MN) vs. methyl-
4,6-d2-nicotinate (d2-MN) in human cancer cell lines.






Figure 2. Effect of deuterated solvent mixture on cell viability: MTT cell via-
bility assays performed on the indicated cell lines after A) 6 h and B) 24 h of
treatment with deuterated solvents at various ratios. The final solvent
volume in the cell culture medium was 10%. EtOD= [D6]ethanol. Data are
the mean+SD. *P<0.05, **P<0.005, ns: not significant vs. untreated con-
trol (100% viable) ; one-way ANOVA.
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mal biocompatibility it is important to consider the duration of
exposure on cells in culture (or in vivo) when performing
SABRE using solvent with higher (>30%) [D6]ethanol content.
As the optimal solvent mixture for biocompatibility deter-
mined here is 30% [D6]ethanol in D2O, we wished to quantify
the effects of using this solvent directly for the SABRE polariza-
tion of d2-MN. Thus, we prepared a sample containing 5 mm
[IrCl(COD)(IMes)] , 20 mm d2-MN in [D6]ethanol in D2O (30:70).
After exposure to p-H2 at 3 bar and 298 K in a magnetic field
of 60 G we observed a 105:22-fold total signal enhancement
at 9.4 T. The corresponding 1H NMR spectra are shown in the
Supporting Information (Figure S3). This is a significant de-
crease in polarization relative to the use of 100% [D6]ethanol
as solvent, and polarization under 3 bar p-H2 gave a signal en-
hancement of >2800-fold.[7] As we have previously shown, fur-
ther optimization may be achieved by using a higher pressure
of p-H2 and isotopically labeled catalysts, and work is ongoing
to improve the polarization levels.
Evaluating the cytotoxicity of substrate in solvent
Having found that 30% [D6]ethanol in D2O does not induce
toxicity to cells in vitro, we then performed viability assays for
d2-MN dissolved in this solvent mixture. Again, we compared
d2-MN with MN to exclude any toxic effects that arise from the
selective deuteration in d2-MN when dissolved in alcohol sol-
vents. Importantly, d2-MN shows good solubility in this solvent
composition and it did not decrease the viability of A549 and
MCF7 cells when treated for up to 6 h (Figure 3A,B, respective-
ly). However, longer treatment times at concentrations higher
than 5 mm are shown to affect the viability of both cell lines
(Figure 3C,D). Surprisingly, as shown in Figure 3D, when com-
pared with MN, d2-MN induced a significant decrease in the vi-
ability of MCF7 cells at this concentration (5 mm) when treated
for long time (24 h). This further indicates that deuteration
might affect the toxicity effects of the substrate either by itself,
or that toxicity is more pronounced as an additive effect when
mixed in alcohol solvent at this long exposure time (24 h). To-
gether, our data suggest that the in vitro cytotoxicity of d2-MN
in an [D6]ethanol/D2O solvent mixture depends on the dura-
tion of exposure on cells in culture. It is worth mentioning that
the aim of our cytotoxicity assessment is to allow us to under-
stand the transient effect these compounds or solvents play
under the stated conditions. We are aware that in an in vivo
setting, biocompatibility would be dependent on physiological
status and the pharmacokinetics of the organism and the
mechanism of action of the treated material. Nonetheless, the
SABRE approach requires the contrast agent to stay in the
body for a comparatively short time prior to excretion, as relax-
ation limits utility and further reduces toxicity concerns.
Evaluating the biocompatibility of SABRE reaction mixture
Given that the cytotoxic dosage of d2-MN in the solvent
[D6]ethanol/D2O (30:70) is well above the amounts used for a
typical SABRE reaction (considering only less than or equal to
10% will be taken as a bolus for treatment) we sought to in-
vestigate the effect of the SABRE reaction mixture on A549
and MCF7 cell lines. For this, we prepared a typical SABRE solu-
tion containing 5 mm of [IrCl(COD)(IMes)] together with 20 mm
d2-MN in [D6]ethanol/D2O (30:70) and activated it with 3 bar
H2. We exposed the cells to various bolus volumes (1.25, 2.5, 5,
and 10%) of the activated mixture and assessed the viability of
the cells at different time periods by MTT assay. As illustrated
in Figure 4, treatment with the SABRE reaction mixture over a
short period of time (1 h) did not decrease the viability of
A549 and MCF7 cells when the lowest volume (e.g. , 1.25%)
was added to the cell culture medium. However, cells that
were treated with 10% bolus of the SABRE reaction mixture
showed less viability at the same time point.
To distinguish the cytotoxic effect of the substrate and cata-
lyst in the mixture we prepared, in parallel, analogous solu-
tions containing various concentrations of either d2-MN or
[IrCl(COD)(IMes)] alone. Unfortunately, [IrCl(COD)(IMes)] is less
soluble in [D6]ethanol/D2O (30:70) and, moreover, cannot form
an active catalyst without the presence of a substrate when ac-
tivated with H2. Under these conditions, a precipitate formed
(Supporting Information Figure S4), and cytotoxicity assess-
Figure 3. Cytotoxicity of alcohol-solubilized methyl nicotinate: MTT cell via-
bility data showing A),C) A549 and B),D) MCF7 cells treated for 6 h (upper
panel) and 24 h (lower panel) with various dilutions of MN and d2-MN solu-
bilized in 30% [D6]ethanol in D2O. The final solvent volume in the cell cul-
ture medium was 10%. Data are the mean+SD from three independent ex-
periments (n=3). Statistically significant differences from untreated control
group (or from protio form of MN) are shown. *P<0.05, ns: not significant
vs. untreated control group; one-way ANOVA.
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ment using this emulsion to treat cells is not expected to pro-
vide comparable results. Nevertheless, we treated the cells
with a solution of d2-MN alone, and no adverse effect was ob-
served even at treatments over 24 h on both cell lines. This in-
dicates that the deleterious effect of the SABRE reaction mix-
ture on cells could be due to the presence of the catalyst and
not the substrate (Supporting Information Figure S5). In con-
trast, the cells treated with various bolus volumes of [IrCl(CO-
D)(IMes)] , prepared by homogeneous mixing of the precipitate,
showed loss of cell viability at higher volumes and short time
points (Supporting Information Figure S6). Together these data
indicate that the SABRE reaction mixture induces a decrease in
cell viability at higher volumes, and this is likely due to the
presence of activated catalyst. We therefore conclude that in
order to achieve biocompatibility, the amount of activated cat-
alyst must be either decrease or eliminated.
Method of catalyst deactivation and removal
We have thus developed a protocol to remove the SABRE cata-
lyst from solution. The addition of a chelating ligand to the
SABRE reaction prevents reversible exchange of the substrate,
deactivating the SABRE process without affecting the polariza-
tion levels whilst extending T1 relaxation times.
[15] We postulat-
ed that the addition of bathophenanthrolinedisulfonic acid
disodium salt (BPS) would see it irreversibly bind to the iridium
center whilst giving an opportunity to remove the resultant
species via ion-exchange chromatography. This procedure is
shown schematically in Figure 5. First, we prepared the activat-
ed SABRE reaction mixture in [D6]ethanol/D2O solution prior to
the addition of a solution of 2.0 equiv of BPS in D2O. Following
the reaction by 1H NMR spectroscopy reveals the immediate
formation of a new hydride species at d@19.6 ppm which we
attribute to [Ir(IMes)(BPS)(d2-MN)(H)2]Cl and confirmed by LC–
MS (Supporting Information Figure S7). After filtration through
DEAE-SephadexS with D2O as eluent, less than 2% of the cata-
lyst remains in solution with high mass recovery of d2-MN,
which can be delivered in the biocompatible [D6]ethanol/D2O
solvent mixtures. This protocol is therefore efficient at remov-
ing the SABRE catalyst from solution. Importantly, the hyperpo-
larized SABRE signal is still visible after the deactivation and
depletion steps. The total signal gains were 74:21-fold which
represents a 30% decrease in signal relative to the standard
SABRE sample in [D6]ethanol/D2O (30:70).
1H NMR spectra are
shown in the Supporting Information (Figure S7). As the deac-
tivation and depletion process takes a minimum of 12 seconds
longer than a standard sample measurement, we attribute the
loss to relaxation effects.
Cytotoxicity assessment of catalyst depleted SABRE mixture
The cytotoxicity of the catalyst-depleted samples on cells was
then evaluated by taking different volumes (1.25, 2.5, 5, and
10%) of the reconstituted mixture in [D6]ethanol/D20 (30:70)
and by following the treatment conditions in the same manner
as performed with the non-quenched SABRE reaction mixture.
Pleasingly, 10% of the bolus containing the catalyst-depleted
SABRE reaction mixture did not alter the viability of A549 cells
for up to 6 h of treatment (Figure 6A). Similarly, MCF7 cells
showed no changes in cell viability when treated with higher
volumes (10%) of the catalyst-depleted SABRE mixture for up
to 1 h and for up to 6 h with lower volumes (,5%, Figure 6B).
However, longer treatments (24 h) showed significant decrease
at both lower and higher volumes in both cell lines (Fig-
ure 6A,B). It is noted that when extrapolating to an in vivo
model, it is unlikely to show the same long-term toxicity due
to higher metabolic activity and detoxification mechanisms. To-
gether these data indicate that deactivation and removal of
the catalyst could overcome the adverse effect of the SABRE
reaction mixture when treating live cells under the conditions
used here.
Achieving biocompatible SABRE by biphasic catalysis
We hypothesized that using the recently reported biphasic ap-
proach to SABRE catalysis could be a more rapid and facile
Figure 4. Evaluating the biocompatibility of SABRE reaction mixture: A) A549 and B) MCF7 cells were treated with various bolus volumes (0, 1.25, 2.5, 5, and
10%) of SABRE reaction mixture, and cell viability was assessed 1, 6, and 24 h thereafter by MTT assay. Data are the mean+SD from three independent ex-
periments (n=3). *P<0.05, **P<0.005, ns: not significant vs. untreated control (100% viable) ; one-way ANOVA.
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way to deplete the solution of the iridium catalyst.[16] In this
method the SABRE catalyst is located in a chloroform or di-
chloromethane phase and minimally in the aqueous phase.
Conversely, the hyperpolarized substrate is distributed be-
tween the two. For toxicity assessment on cells, the aqueous
phase was isolated, and various bolus volumes (2.5, 5.0, 7.5,
and 10%) were added to the cell culture medium. We per-
formed the appropriate viability assay at different time points
as illustrated in the previous sections. Treatment with the
phase-separated SABRE mixture did not decrease the viability
of either A549 or MCF7 cells at any of the time points tested
(Figure 7). The minimal cytotoxic effect observed here is similar
to the effect seen when treated with the substrate alone (Sup-
porting Information Figure S9). This result indicates that the cy-
totoxicity associated with the SABRE reaction mixture is negat-
ed by this method. While we are able to produce a biocompat-
ible bolus by this phase-separation method, the polarization
level achieved by the biphasic catalysis is approximately 2000-
fold for the same substrate (d2-MN), (Supporting Information
Figure S10). Nevertheless, we conclude that polarization in the
biphasic mixture is higher than that observed in an
[D6]ethanol/D2O solution under 3 bar p-H2 and at 298 K.
Figure 5. Schematic presentation of the catalyst deactivation procedure: 1. Activation: The active catalyst is formed through reaction of [IrCl(COD)(IMes)] , d2-
MN, and H2 in [D6]ethanol/D2O (30:70) solution. 2. Deactivation: Addition of BPS leads to immediate formation of the deactivated catalyst [Ir(IMes)(BPS)(d2-
MN)(H)2]Cl as confirmed by
1H NMR spectroscopy and LC–MS. 3. Depletion: Ion-exchange chromatography on DEAE-SephadexS leads to <2% catalyst con-
tamination.
Figure 6. Achieving biocompatible SABRE by deactivating the catalyst : MTT viability assay showing A) A549 and B) MCF7 cells treated with various volumes of
catalyst-depleted SABRE reaction mixture for 1, 6, and 24 h. Data are the mean+SD from three independent experiments (n=3). *P<0.05, **P<0.005, ns:
not significant vs. untreated control (100% viable) ; one-way ANOVA.
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Conclusions
In summary, we have shown through in vitro cytotoxicity stud-
ies that it is possible to create a biocompatible SABRE bolus
for future in vivo detection. This is an important step toward
preclinical/clinical disease-state diagnosis using SABRE technol-
ogy. We have exemplified our toxicity study for methyl-4,6-d2-
nicotinate (d2-MN), which shows strong hyperpolarization
levels and long magnetic lifetimes.[7] By determination of the
IC50 values across a number of human cancer cell lines we
have shown that deuteration of the substrate does not show
significant change in toxicology relative to its protio analogue.
This will provide important information for the future develop-
ment of SABRE contrast agents. We will also determine the ef-
fects of other common isotopic labeling strategies (e.g. , 13C
and 15N) as we further expand our substrate profile. For exam-
ple, we are interested in the tuberculosis drug isoniazid[17] and
molecules that can sustain long-lived singlet states.[4f, 18] The
solvent composition was shown to have a substantial effect on
cell survival rate in an in vitro assay; 100% [D6]ethanol pro-
duced adverse effects on the cells over time periods of up to
6 h. We overcame this by dilution with D2O and found that a
[D6]ethanol/D2O ratio of 30:70 showed no cell death over 24 h.
Again, solvent deuteration had no effect over their protio ana-
logues.
We have shown that the iridium catalyst is the largest con-
tributor to decreasing the viability of cells in the SABRE mix-
ture. Therefore, we have developed a simple and robust
method to remove it from solution by ion-exchange chroma-
tography. To achieve this we add bathophenanthrolinedisulfon-
ic acid disodium salt (BPS) and subsequently flush the solution
through DEAE-SephadexS. The eluent from this procedure
showed minimal adverse effects on a number of cell lines for
up to 6 h exposure and retained 70% of the initial SABRE-in-
duced polarization. Furthermore, the recently reported bipha-
sic approach to SABRE catalysis has also been shown to lead
to bolus biocompatibility after separation of the aqueous
phase.
We are currently working toward the development of an au-
tomated delivery method that includes all of the proposed de-
activation, depletion, or separation methods to exclude the
catalyst that can be used in a clinical setting. Additionally, as
the SABRE catalyst is the main source of toxicity, we are con-
sidering synthetic strategies to decrease toxicity through fur-
ther changes to the catalyst.
Experimental Section
Chemicals and reagents : All chemicals were purchased from
Sigma–Aldrich, Fisher, or Alfa-Aesar. Deuterated solvents
([D6]ethanol, deuterium oxide (D2O), and chloroform-d (CDCl3))
were purchased from Sigma. The following compounds were pre-
pared according to published procedures: methyl-4,6-d2-nicoti-
nate[7] and [IrCl(COD)(IMes)] .[19]
Cell culture : Human alveolar adenocarcinoma cells (A549), breast
cancer cells (MCF7), and cervical cancer cells (HeLa) were kindly
provided by Prof. Christoph Borner (IMMZ, Freiburg, Germany). The
human breast adenocarcinoma cell line MDA-MB-231 was a gift
from Prof. Thomas Kaufmann (University of Bern, Switzerland). All
cell lines were grown in DMEM supplemented with 10% fetal
bovine serum (FBS), penicillin (100 UmL@1), streptomycin
(100 mgmL@1), and l-glutamine (2 mm) (all from Gibco Life Technol-
ogies). The cells were maintained in a humidified atmosphere
under standard conditions (37 8C, 5% CO2). The media were
changed at regular intervals, and upon reaching appropriate con-
fluence (90%) the cells were passaged after brief exposure to a
trypsin/EDTA solution (Invitrogen).
Treatment of cells : Immediately after trypsin/EDTA treatment,
viable cells were counted in a hemocytometer by Trypan blue
(Sigma) exclusion. The required number of cells (normally 104 per
well in a 96-well tissue culture plate (Nunc)) was seeded 24 h
before treatment so that they are in exponential growth phase at
the start of the experiment. Before treatment various volumes of
the bolus from substrate, catalyst, or the SABRE reaction mixture
were diluted to a maximum of 10 mL in the same solvent from
which the compounds were originally prepared. For cell assays,
throughout this study (unless otherwise indicated) we kept the
final amount of the solvent at 10% in the total volume of the cell
growth medium (i.e. , 10 mL in 100 mL).
Figure 7. Evaluating the biocompatibility of biphasic SABRE reaction mixture: MTT viability assay showing A) A549 and B) MCF7 cells treated with various vol-
umes (0, 2.5, 5, 7.5, and 10%) of the bolus from the aqueous fraction of a SABRE reaction in biphasic solvents for 1, 6, and 24 h. Data are the mean+SD from
three independent experiments (n=3).
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MTT assay : The MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) assay is a commonly used colorimetric
method to determine in vitro cytotoxicity of the given compound
by means of a functional mitochondrial dehydrogenase activity in
living cells.[12] In this method, MTT tetrazolium is reduced to insolu-
ble formazan crystals and it is directly proportional to the number
living cells. Therefore, this assay represents a measure for cell via-
bility as well. For this assay, cells (normally 104 cells per well in a
96-well plate) were taken in triplicates and treated with a range of
compounds (see above) or kept as cell viability control with no
compound treatment (untreated) in cell growth media. After incu-
bation at desired time points the cell growth media was replaced
with fresh media (100 mL) and incubated with 10 mL of MTT
(5 mgmL@1, dissolved in cell growth media and filter sterilized
(0.22 mm)) for 4 h in a humidified atmosphere at 37 8C. The
medium with MTT was then carefully aspirated, and the formed
formazan crystals were solubilized in 100 mL of dimethyl sulfoxide
(DMSO). The absorbance of the colored (purple) solution was then
measured at 570 nm using a microplate reader (MultiskanGO, Ther-
moFisher). The absorbance values (averaged out of triplicates)
were blanked against DMSO, and the absorbance of cells exposed
to cell growth medium only (i.e. , untreated) was taken as 100%
viable (i.e. , control). The cell viability of the compound-treated
samples were then calculated by normalizing to the untreated con-
trol sample and are normally expressed as percent of control. Each
assay was repeated a minimum of three times for statistical analy-
sis of the data.
Evaluation of IC50 : Compounds were dissolved in cell growth
media, and cells were treated with various concentrations of the
compound (ranging from a maximum of 80 mm to a minimum of
1.25 mm) in 1=2 serial dilutions. Cell viability was analyzed by MTT
assay after 48 h treatment. IC50 values of MN and d2-MN were cal-
culated by using GraphPad Prism software (version 5.0).
Catalyst deactivation and removal : A solution of [IrCl(COD)(IMes)]
(5 mm) and d2-MN (20 mm, 4.0 equiv) in [D6]ethanol/D2O (30:70,
total volume: 3.0 mL) was degassed prior to the introduction of hy-
drogen at a pressure of 3 bar. After 5 min, the sample was opened
to air, and a solution of bathophenanthrolinedisulfonic acid disodi-
um salt hydrate (BPS) (10 mm, 2.0 equiv) in water (1.0 mL) was
added. The resulting suspension was eluted through DEAE-Sepha-
dexS (2.5 g) with water (11 mL). For treatment on cells the eluent
was vacuum dried and reconstituted in 30% [D6]ethanol in D2O.
Prior to treatment various volumes of the bolus were further dilut-
ed as indicated above.
Biphasic SABRE—biphasic separation : A solution of [IrCl(CO-
D)(IMes)] (5 mm) and d2-MN (20 mm, 4.0 equiv) in CDCl3 (1.5 mL)
and D2O (containing 0.9% NaCl) (1.5 mL) was mixed together and
was degassed prior to the introduction of hydrogen at a pressure
of 3 bar. After phase separation the aqueous layer was removed,
and prior to treatment various volumes of the bolus were further
diluted as indicated above.
Statistical analysis : All experiments were performed at least three
times (n=3), and all data are presented as the mean and standard
deviation (SD) of the mean. The significance of the differences be-
tween treated samples and the untreated control was assessed by
one-way analysis of variance (ANOVA) using GraphPad Prism soft-
ware (version 5.0). Statistical significance was set at P values <0.05.
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